MedTrace Logo

Adolescent Mite Allergy Safety Evaluation

NCT04541004 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 253

Last updated 2023-07-03

Study results available
· View outcomes & findings →

Summary

This is a 28-day clinical trial studying the safety of the house dust mite tablet in adolescents with allergic rhinitis/rhinoconjunctivitis.

The purpose of this trial is to collect additional safety information about a tablet used to treat house dust mite allergies, when used to treat adolescents who have these allergies.

The trial medication used is already approved to treat allergic rhinitis caused by house dust mite in adults and adolescents (12-17 years old) in several countries.

Conditions

  • Allergic Rhinitis
  • Allergic Rhinoconjunctivitis

Interventions

BIOLOGICAL

HDM SLIT-tablet

Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)

Sponsors & Collaborators

Principal Investigators

  • Andreas Horn, MD · HNO Praxis am Neckar

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-23
Primary Completion
2021-04-24
Completion
2021-04-24

Countries

  • Czechia
  • Germany
  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04541004 on ClinicalTrials.gov